<p>ABVC BioPharma（納斯達克代碼：ABVC - 獲取免費報告）於週三發佈了季度財報。該公司報告每股收益為（$0.13），據 Zacks 報道。ABVC BioPharma 的股本回報率為負 29.62%，淨利潤率為負 963.46%。</p>
<p>獲取 <strong>ABVC BioPharma</strong> 的提醒：</p>
<h2>ABVC BioPharma 股價上漲 1.0%</h2>
<p>週三中午交易時，ABVC BioPharma 的股票上漲了$0.03，達到$2.97。該股票交易量為 77,893 股，而其平均交易量為 482,299 股。該公司的市值為 5044 萬美元，市盈率為-22.85，貝塔值為 0.27。該公司 50 日簡單移動平均線為$2.72，200 日簡單移動平均線為$1.52。ABVC BioPharma 的 52 周最低價為$0.40，52 周最高價為$5.48。</p>
<h2>機構投資者對 ABVC BioPharma 的看法</h2>
<p>一家機構投資者最近增加了對 ABVC BioPharma 股票的持倉。根據其最近向證券交易委員會（SEC）提交的文件，Geode Capital Management LLC 在第二季度將其在 ABVC BioPharma, Inc.（納斯達克代碼：ABVC - 免費報告）中的持倉增加了 5.8%。該基金在本季度額外購買了 6,017 股後，持有該公司 110,499 股股票。根據其最近的 SEC 文件，Geode Capital Management LLC 持有的 ABVC BioPharma 股票約佔 0.65%，價值 246,000 美元。11.38% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 ABVC BioPharma</h2>
<p>（獲取免費報告）</p>
<p>ABVC BioPharma, Inc 是一家臨牀階段的生物製藥公司，開發藥物和醫療設備以滿足美國未滿足的醫療需求。該公司正在開發 ABV-1501，目前處於 II 期臨牀試驗中，是一種用於三陰性乳腺癌的聯合療法；ABV-1504 已完成 II 期臨牀試驗，針對重度抑鬱症；ABV-1505 目前處於 II 期臨牀試驗中，針對成人注意力缺陷多動障礙；ABV-1703 目前處於 II 期臨牀試驗中，治療轉移性胰腺癌；ABV-1702 目前處於 II 期臨牀試驗中，治療骨髓增生異常綜合症；ABV-1601 目前處於 I/II 期臨牀試驗中，治療癌症患者的抑鬱症。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 ABVC BioPharma</li>
<li>寵物是大生意：4 只值得加入您投資組合的大型寵物股票</li>
<li>亞馬遜的空頭們已舉白旗——值得期待</li>
<li>什麼是空頭頭寸？如何使用它</li>
<li>Tempus AI 強勁的第二季度推動增長故事——未來還有更多上升空間？</li>
<li>特殊目的收購公司（SPAC）您需要知道的事項</li>
<li>CAVA 的蜜月以 16% 的股價下跌結束</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWQw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資$1,000 在 ABVC BioPharma 嗎？</h2>
<p>在您考慮 ABVC BioPharma 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ABVC BioPharma 並不在名單上。</p>
<p>雖然 ABVC BioPharma 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ABVC

<p>ABVC BioPharma（納斯達克代碼：ABVC）公佈了其季度財報，每股虧損為（$0.13）。該公司的股本回報率為負 29.62%，淨利潤率為 963.46%。股價上漲 1.0%，至$2.97，市值為 5044 萬美元。機構投資者持有該股票的 11.38%，Geode Capital Management 將其持倉增加了 5.8%。ABVC BioPharma 正在為多種醫療條件開發幾種處於臨牀試驗階段的藥物</p>

<p>ABVC BioPharma (NASDAQ:ABVC - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, Zacks reports. ABVC BioPharma had a negative return on equity of 29.62% and a negative net margin of 963.46%.</p>
<div class="lb-trans"><p>ABVC BioPharma（納斯達克代碼：ABVC - 獲取免費報告）於週三發佈了季度財報。該公司報告每股收益為（$0.13），據 Zacks 報道。ABVC BioPharma 的股本回報率為負 29.62%，淨利潤率為負 963.46%。</p>
</div><p>Get <strong>ABVC BioPharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>ABVC BioPharma</strong> 的提醒：</p>
</div><h2>ABVC BioPharma Trading Up 1.0%</h2>
<div class="lb-trans"><h2>ABVC BioPharma 股價上漲 1.0%</h2>
</div><p>Shares of ABVC BioPharma stock traded up $0.03 during mid-day trading on Wednesday, reaching $2.97. 77,893 shares of the stock were exchanged, compared to its average volume of 482,299. The company has a market cap of $50.44 million, a price-to-earnings ratio of -22.85 and a beta of 0.27. The firm has a 50-day simple moving average of $2.72 and a 200 day simple moving average of $1.52. ABVC BioPharma has a fifty-two week low of $0.40 and a fifty-two week high of $5.48.</p>
<div class="lb-trans"><p>週三中午交易時，ABVC BioPharma 的股票上漲了$0.03，達到$2.97。該股票交易量為 77,893 股，而其平均交易量為 482,299 股。該公司的市值為 5044 萬美元，市盈率為-22.85，貝塔值為 0.27。該公司 50 日簡單移動平均線為$2.72，200 日簡單移動平均線為$1.52。ABVC BioPharma 的 52 周最低價為$0.40，52 周最高價為$5.48。</p>
</div><h2>Institutional Investors Weigh In On ABVC BioPharma</h2>
<div class="lb-trans"><h2>機構投資者對 ABVC BioPharma 的看法</h2>
</div><p>An institutional investor recently raised its position in ABVC BioPharma stock. Geode Capital Management LLC increased its position in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC - Free Report) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,499 shares of the company's stock after acquiring an additional 6,017 shares during the quarter. Geode Capital Management LLC owned about 0.65% of ABVC BioPharma worth $246,000 as of its most recent SEC filing. 11.38% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家機構投資者最近增加了對 ABVC BioPharma 股票的持倉。根據其最近向證券交易委員會（SEC）提交的文件，Geode Capital Management LLC 在第二季度將其在 ABVC BioPharma, Inc.（納斯達克代碼：ABVC - 免費報告）中的持倉增加了 5.8%。該基金在本季度額外購買了 6,017 股後，持有該公司 110,499 股股票。根據其最近的 SEC 文件，Geode Capital Management LLC 持有的 ABVC BioPharma 股票約佔 0.65%，價值 246,000 美元。11.38% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About ABVC BioPharma</h2>
<div class="lb-trans"><h2>關於 ABVC BioPharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.</p>
<div class="lb-trans"><p>ABVC BioPharma, Inc 是一家臨牀階段的生物製藥公司，開發藥物和醫療設備以滿足美國未滿足的醫療需求。該公司正在開發 ABV-1501，目前處於 II 期臨牀試驗中，是一種用於三陰性乳腺癌的聯合療法；ABV-1504 已完成 II 期臨牀試驗，針對重度抑鬱症；ABV-1505 目前處於 II 期臨牀試驗中，針對成人注意力缺陷多動障礙；ABV-1703 目前處於 II 期臨牀試驗中，治療轉移性胰腺癌；ABV-1702 目前處於 II 期臨牀試驗中，治療骨髓增生異常綜合症；ABV-1601 目前處於 I/II 期臨牀試驗中，治療癌症患者的抑鬱症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than ABVC BioPharma</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>Amazon’s Bears Have Raised the White Flag—Get Excited</li>
<li>What is Short Interest? How to Use It</li>
<li>Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>CAVA’s Honeymoon Ends With a 16% Stock Drop</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 ABVC BioPharma</li>
<li>寵物是大生意：4 只值得加入您投資組合的大型寵物股票</li>
<li>亞馬遜的空頭們已舉白旗——值得期待</li>
<li>什麼是空頭頭寸？如何使用它</li>
<li>Tempus AI 強勁的第二季度推動增長故事——未來還有更多上升空間？</li>
<li>特殊目的收購公司（SPAC）您需要知道的事項</li>
<li>CAVA 的蜜月以 16% 的股價下跌結束</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWQw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ABVC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ABVC BioPharma Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資$1,000 在 ABVC BioPharma 嗎？</h2>
</div><p>Before you consider ABVC BioPharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 ABVC BioPharma 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABVC BioPharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ABVC BioPharma 並不在名單上。</p>
</div><p>While ABVC BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ABVC BioPharma 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ABVC BioPharma（NASDAQ 代碼：ABVC）公佈季度財報結果